Rocket One (RKTO) Research & Development (2018 - 2026)
Rocket One's (RKTO) quarterly Research & Development came in at $2.0 million in Q2 2026, up 88.07% year-over-year from $1.0 million in Q2 2025, and up 28.73% quarter-over-quarter from $1.5 million in Q1 2026.
Analysis
Rocket One (RKTO) Research & Development (2018 - 2026) Analysis & Trends
Rocket One has disclosed Research & Development across 9 years of filings, most recently posting $2.0 million for Q2 2026.
- In Q2 2026, Research & Development rose 88.07% year-over-year to $2.0 million; the TTM figure through Jun 2026 stood at $6.4 million (up 27.64% YoY), while the FY2025 annual figure was $5.9 million, up 83.02% from the prior year.
- Research & Development came in at $2.0 million for Q2 2026 at Rocket One, up from $1.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.0 million in Q1 2025 to a low of -$3.4 million in Q4 2022.
- Average Research & Development over 5 years is $912308.1, with a median of $1.0 million recorded in 2024.
- Year-over-year, Research & Development slumped 44.55% in 2022 and soared 242.63% in 2025.
- Over 5 years, Research & Development stood at -$3.4 million in 2022, then surged by 123.71% to $796763.0 in 2023, then jumped by 30.4% to $1.0 million in 2024, then advanced by 26.53% to $1.3 million in 2025, then soared by 48.75% to $2.0 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $2.0 million in Q2 2026, $1.5 million in Q1 2026, and $1.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Rocket One | 13.87 Mn | 5.98 Mn | - | 1.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Mn |
| Mar 31, 2026 | 1.52 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 994,474.00 |
| Jun 30, 2024 | 644,025.00 |
| Mar 31, 2024 | 571,642.00 |
| Dec 31, 2023 | 796,763.00 |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 663,999.00 |
| Mar 31, 2023 | 942,886.00 |
| Dec 31, 2022 | -3.36 Mn |
| Sep 30, 2022 | 1.45 Mn |
| Jun 30, 2022 | 971,182.00 |
| Mar 31, 2022 | 948,379.00 |
| Dec 31, 2021 | -4.44 Mn |
| Sep 30, 2021 | 2.12 Mn |